Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | BACE1 | P56817 | 8/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10155887 | 0.84 | BACE1 (0.59) | GAABACE1MAPT | |
| SCHEMBL10155162 | 0.83 | KMT2A (0.49) | GAAMEN1KMT2ABACE1LMNA | |
| SCHEMBL10156589 | 0.82 | BACE1 (0.57) | BACE1 | |
| SCHEMBL10156170 | 0.82 | BACE1 (0.61) | BACE1 | |
| SCHEMBL10155276 | 0.81 | BACE1 (0.55) | BACE1 | |
| SCHEMBL10157518 | 0.80 | BACE1 (0.54) | BACE1 | |
| SCHEMBL14144328 | 0.80 | BACE1 (0.54) | BACE1 | |
| SCHEMBL10155419 | 0.80 | BACE1 (0.66) | MEN1KMT2ABACE1POLB | |
| SCHEMBL10157285 | 0.80 | HDAC2 (0.47) | MEN1KMT2ABACE1NAMPT | |
| SCHEMBL10157767 | 0.79 | BACE1 (0.53) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150210680-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO (JP) | 2015-07-30 | — | — | US | disclosed |
| US-20150210680-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO (JP) | 2015-07-30 | — | — | US | disclosed |
| US-9029358-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2015-05-12 | — | — | US | disclosed |
| US-9029358-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2015-05-12 | — | — | US | disclosed |
| US-8895548-B2 | Pharmaceutical composition for treating alzheimer's disease | SHIONOGI & CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895548-B2 | Pharmaceutical composition for treating alzheimer's disease | SHIONOGI & CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8815851-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2014-08-26 | — | — | US | disclosed |
| US-8815851-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2014-08-26 | — | — | US | disclosed |
| US-20140058097-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | SHIONOGI & CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20140058097-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | SHIONOGI & CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20130158260-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2013-06-20 | — | — | US | disclosed |
| US-20130158260-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2013-06-20 | — | — | US | disclosed |
| US-8173642-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8173642-B2 | Aminodihydrothiazine derivatives | SHIONOGI & CO., LTD. (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20120022249-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-20120016116-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20100160290-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | SHIONOGI & CO., LTD. (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20100160290-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | SHIONOGI & CO., LTD. (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20090082560-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082560-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016116-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | GAA 1928/4885CA1 1156/4885CA2 2411/4885 |
| US-20100160290-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | NR1H2, NR1H3, NR0B1 | GAA 2383/4885CA1 736/4885CA2 2298/4885 |
| US-20130158260-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | GAA 930/4885CA1 1221/4885CA2 1786/4885 |
| US-20140058097-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE | NR1H2, NR1H3, NR0B1 | GAA 2550/4885CA1 726/4885CA2 2323/4885 |
| US-20120022249-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | GAA 1928/4885CA1 1156/4885CA2 2411/4885 |
| US-20150210680-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | GAA 1928/4885CA1 1156/4885CA2 2411/4885 |
| US-20090082560-A1 | AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, BACE2, APP | GAA 1928/4885CA1 1156/4885CA2 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.